• In recent days, Liquidia Corporation announced its upcoming first-quarter 2026 earnings release, alongside expectations from analysts for higher earnings per share and stronger revenue than the prior year, while also disclosing CEO-related insider share sales executed under pre-set Rule 10b5-1 trading plans.
• The combination of anticipated earnings growth tied to Liquidia’s pulmonary hypertension franchise and insider transactions has sharpened investor focus on how its PRINT-enabled therapies could translate into financial performance and business momentum.
• We’ll now examine how the anticipated earnings jump, against a backdrop of insider selling activity, may influence Liquidia’s broader investment narrative.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Liquidia Investment Narrative Recap

To own Liquidia, you need to believe its PRINT enabled pulmonary hypertension franchise can mature into a durable, cash generating business, with YUTREPIA and pipeline assets like L606 supporting that story. In the near term, the key catalyst is the upcoming Q1 2026 earnings report, where analysts expect higher EPS and revenue versus last year, while a major risk remains execution around payer economics and demand for expanded manufacturing capacity. Recent insider selling under Rule 10b5-1 plans does not appear to alter these fundamentals in a material way.

The most relevant recent announcement is the scheduled Q1 2026 release on May 11, where consensus calls for EPS of US$0.34 and significantly higher revenue than the prior year. Against the backdrop of CEO affiliated share sales, this earnings print may help investors gauge how early YUTREPIA uptake, gross to net dynamics and initial operating leverage are tracking against expectations, and whether the current growth profile supports the company’s capacity expansion and ongoing legal and pipeline commitments.

Yet beneath the strong early numbers, investors should be aware of how reimbursement terms and gross to net adjustments could eventually affect reported revenue and margins...

Liquidia's narrative projects $717.7 million revenue and $299.9 million earnings by 2029. This requires 118.1% yearly revenue growth and a $424.0 million earnings increase from -$124.1 million today.

Uncover how Liquidia's forecasts yield a $44.00 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Before this news, the most pessimistic analysts were still assuming revenue could reach about US$555.6 million and earnings US$23.4 million by 2028, yet they remain far more cautious than the base case and highlight how expectations around litigation outcomes and payer pressure could shift as new information arrives.

Explore 5 other fair value estimates on Liquidia - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Liquidia research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Liquidia research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Liquidia's overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.